Construction of an MRNA-miRNA-lncRNA Network Prognostic for Triple-negative Breast Cancer

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2021 Jan 11

PMID 33428596

Citations 17

Authors

Yuan Huang

Xiaowei Wang

Yiran Zheng

Wei Chen

Yabing Zheng

Guangliang Li

Weiyang Lou

Xiaojia Wang

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to establish a novel competing endogenous RNA (ceRNA) network able to predict prognosis in patients with triple-negative breast cancer (TNBC). Differential gene expression analysis was performed using the GEO2R tool. Enrichr and STRING were used to conduct protein-protein interaction and pathway enrichment analyses, respectively. Upstream lncRNAs and miRNAs were identified using miRNet and mirTarBase, respectively. Prognostic values, expression, and correlational relationships of mRNAs, lncRNAs, and miRNAs were examined using GEPIA, starBase, and Kaplan-Meier plotter. It total, 860 upregulated and 622 downregulated differentially expressed mRNAs were identified in TNBC. Ten overexpressed and two underexpressed hub genes were screened. Next, 10 key miRNAs upstream of these key hub genes were predicted, of which six upregulated miRNAs were significantly associated with poor prognosis and four downregulated miRNAs were associated with good prognosis in TNBC. NEAT1 and MAL2 were selected as key lncRNAs. An mRNA-miRNA-lncRNA network in TNBC was constructed. Thus, we successfully established a novel mRNA-miRNA-lncRNA regulatory network, each component of which is prognostic for TNBC.

Citing Articles

Deciphering the code: the pivotal role of lncRNAs in advancing TNBC therapy.

Chen W, Pan Z, Feng Z, Wang X, Zhu S Front Oncol. 2024; 14:1450980.

PMID: 39286016 PMC: 11402698. DOI: 10.3389/fonc.2024.1450980.

Inhibition of MiR-155 Using Exosomal Delivery of Antagomir Can Up-Regulate in Triple Negative Breast Cancer.

Razaviyan J, Sirati-Sabet M, Tafti A, Hadavi R, Karima S, Rajabibazl M Endocr Metab Immune Disord Drug Targets. 2024; 24(14):1664-1676.

PMID: 38424419 DOI: 10.2174/0118715303289859240214103350.

microRNAs expression profile in phyllodes tumors of the breast.

Hachana M, Maatouk M, Lassouad Z, Sriha B, Mokni M Heliyon. 2024; 10(2):e24803.

PMID: 38312609 PMC: 10835222. DOI: 10.1016/j.heliyon.2024.e24803.

SGMS1-AS1/MicroRNA-106a-5p/CPT2 Axis as a Novel Target for Regulating Lactate Metabolism in Colon Cancer.

Ruochen Y, Wenbin J, Chao G, Yuhua Y, Feng Q Technol Cancer Res Treat. 2023; 22:15330338231212071.

PMID: 37926998 PMC: 10629329. DOI: 10.1177/15330338231212071.

Identification of MIR600HG/hsa-miR-342-3p/ANLN network as a potential prognosis biomarker associated with lmmune infiltrates in pancreatic cancer.

Qian B, Liu Q, Wang C, Lu S, Ke S, Yin B Sci Rep. 2023; 13(1):15919.

PMID: 37741887 PMC: 10517933. DOI: 10.1038/s41598-023-43174-y.

References

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Gan Y, Li Y, Li T, Shu G, Yin G . CCNA2 acts as a novel biomarker in regulating the growth and apoptosis of colorectal cancer. Cancer Manag Res. 2018; 10:5113-5124. PMC: 6217169. DOI: 10.2147/CMAR.S176833. View

Byrne J, Maleki S, Hardy J, Gloss B, Murali R, Scurry J . MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer. 2010; 10:497. PMC: 2949808. DOI: 10.1186/1471-2407-10-497. View

Kumar P, Aggarwal R . An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2015; 293(2):247-69. DOI: 10.1007/s00404-015-3859-y. View

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

Xue M, Tao W, Yu S, Yan Z, Peng Q, Jiang F . lncRNA ZFPM2-AS1 promotes proliferation via miR-18b-5p/VMA21 axis in lung adenocarcinoma. J Cell Biochem. 2019; 121(1):313-321. DOI: 10.1002/jcb.29176. View

Dong S, Huang F, Zhang H, Chen Q . Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma. Biosci Rep. 2019; 39(2). PMC: 6390130. DOI: 10.1042/BSR20182306. View

Shi X, Wang H, Wang W, Gu Y . MiR-98-5p regulates proliferation and metastasis of MCF-7 breast cancer cells by targeting Gab2. Eur Rev Med Pharmacol Sci. 2019; 23(7):2847-2855. DOI: 10.26355/eurrev_201904_17562. View

Hakuno F, Takahashi S . IGF1 receptor signaling pathways. J Mol Endocrinol. 2018; 61(1):T69-T86. DOI: 10.1530/JME-17-0311. View

10.

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R . ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015; 12(10):573-83. PMC: 4911210. DOI: 10.1038/nrclinonc.2015.117. View

11.

Wang H, Huo X, Yang X, He J, Cheng L, Wang N . STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 2017; 16(1):136. PMC: 5558651. DOI: 10.1186/s12943-017-0680-1. View

12.

Tam C, Wong J, Tsui S, Zuo T, Chan T, Ng T . LncRNAs with miRNAs in regulation of gastric, liver, and colorectal cancers: updates in recent years. Appl Microbiol Biotechnol. 2019; 103(12):4649-4677. DOI: 10.1007/s00253-019-09837-5. View

13.

Lou W, Liu J, Ding B, Xu L, Fan W . Identification of chemoresistance-associated miRNAs in breast cancer. Cancer Manag Res. 2018; 10:4747-4757. PMC: 6205533. DOI: 10.2147/CMAR.S172722. View

14.

Luan X, Wang Y . LncRNA XLOC_006390 facilitates cervical cancer tumorigenesis and metastasis as a ceRNA against miR-331-3p and miR-338-3p. J Gynecol Oncol. 2018; 29(6):e95. PMC: 6189437. DOI: 10.3802/jgo.2018.29.e95. View

15.

Li X, Wang X, Song W, Xu H, Huang R, Wang Y . Oncogenic Properties of NEAT1 in Prostate Cancer Cells Depend on the CDC5L-AGRN Transcriptional Regulation Circuit. Cancer Res. 2018; 78(15):4138-4149. DOI: 10.1158/0008-5472.CAN-18-0688. View

16.

Bhandari A, Shen Y, Sindan N, Xia E, Gautam B, Lv S . MAL2 promotes proliferation, migration, and invasion through regulating epithelial-mesenchymal transition in breast cancer cell lines. Biochem Biophys Res Commun. 2018; 504(2):434-439. DOI: 10.1016/j.bbrc.2018.08.187. View

17.

Tay Y, Rinn J, Pandolfi P . The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505(7483):344-52. PMC: 4113481. DOI: 10.1038/nature12986. View

18.

Hernandez-Segura A, Nehme J, Demaria M . Hallmarks of Cellular Senescence. Trends Cell Biol. 2018; 28(6):436-453. DOI: 10.1016/j.tcb.2018.02.001. View

19.

Ding K, Li W, Zou Z, Zou X, Wang C . CCNB1 is a prognostic biomarker for ER+ breast cancer. Med Hypotheses. 2014; 83(3):359-64. DOI: 10.1016/j.mehy.2014.06.013. View

20.

Bak R, Mikkelsen J . miRNA sponges: soaking up miRNAs for regulation of gene expression. Wiley Interdiscip Rev RNA. 2013; 5(3):317-33. DOI: 10.1002/wrna.1213. View